

# CITATION REPORT

List of articles citing

The type I interferonopathies: 10 years on

DOI: 10.1038/s41577-021-00633-9

Nature Reviews Immunology, 2021, , .

**Source:** <https://exaly.com/paper-pdf/91252231/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
74	The USP18-FBXO6 axis maintains the malignancy of ovarian cancer.. <i>Biochemical and Biophysical Research Communications</i> , <b>2022</b> , 593, 101-107	3.4	0
73	Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI).. <i>Cells</i> , <b>2022</b> , 11,	7.9	1
72	Type I interferons and SARS-CoV-2: from cells to organisms.. <i>Current Opinion in Immunology</i> , <b>2022</b> , 74, 172-182	7.8	4
71	Haploinsufficiency of PSMD12 causes proteasome dysfunction and subclinical autoinflammation.. <i>Arthritis and Rheumatology</i> , <b>2022</b> ,	9.5	0
70	The Emerging Role of RNA Modifications in the Regulation of Antiviral Innate Immunity.. <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 845625	5.7	0
69	Type-I Interferon Signaling in Fanconi Anemia.. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2022</b> , 12, 820273	5.9	1
68	Emerging Roles of lncRNAs Regulating RNA-Mediated Type-I Interferon Signaling Pathway.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 811122	8.4	1
67	Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 825367	8.4	1
66	STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments.. <i>Cells</i> , <b>2022</b> , 11,	7.9	1
65	GM-CSF Protects Macrophages from DNA Damage by Inducing Differentiation.. <i>Cells</i> , <b>2022</b> , 11,	7.9	1
64	STINGing type I IFN-mediated immunopathology in COVID-19.. <i>Nature Immunology</i> , <b>2022</b> ,	19.1	2
63	Autoinflammatorische Erkrankungen in expandierendes Spektrum. <i>Monatsschrift Fur Kinderheilkunde</i> , <b>2022</b> , 170, 335-340	0.2	
62	Type I interferon-related kidney disorders.. <i>Kidney International</i> , <b>2022</b> ,	9.9	0
61	Regulation of IRF3 activation in Human Antiviral Signalling Pathways.. <i>Biochemical Pharmacology</i> , <b>2022</b> , 115026	6	2
60	Distinct evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates identify important host determinants of COVID-19.		0
59	DNA damage rather than type I IFN signaling is the primary mediator of neural dysfunction in Aicardi-Goutières syndrome after RNASEH2 disruption.. <i>Neuron</i> , <b>2021</b> , 109, 3897-3900	13.9	0
58	Heterozygous PNPT1 variants cause spinocerebellar ataxia type 25.. <i>Annals of Neurology</i> , <b>2022</b> ,	9.4	0

57	Nonresolving inflammation redux.. <i>Immunity</i> , <b>2022</b> , 55, 592-605	32.3	3
56	COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells.. <i>Seminars in Immunopathology</i> , <b>2022</b> , 44, 375	12	1
55	Inborn Errors of Immunity With Fetal or Perinatal Clinical Manifestations. <i>Frontiers in Pediatrics</i> , <b>2022</b> , 10,	3.4	0
54	Genome Replication Is Associated With Release of Immunogenic DNA Waste. <i>Frontiers in Immunology</i> , <b>2022</b> , 13,	8.4	1
53	Disrupting Mechanisms that Regulate Genomic Repeat Elements to Combat Cancer and Drug Resistance. <i>Frontiers in Cell and Developmental Biology</i> , <b>2022</b> , 10,	5.7	1
52	Modelling the within-host spread of SARS-CoV-2 infection, and the subsequent immune response, using a hybrid, multiscale, individual-based model. Part I: Macrophages.		0
51	Disorders of ubiquitylation: unchained inflammation.. <i>Nature Reviews Rheumatology</i> , <b>2022</b> ,	8.1	1
50	DYT-PRKRA Mutation P222L Enhances PACT $\beta$ Stimulatory Activity on Type I Interferon Induction. <i>Biomolecules</i> , <b>2022</b> , 12, 713	5.9	0
49	cGAS/STING-DEPENDENT SENSING OF ENDOGENOUS RNA.		0
48	Dysregulation of the cGAS-STING Pathway in Monogenic Autoinflammation and Lupus. <i>Frontiers in Immunology</i> , 13,	8.4	1
47	ZBP1 sequesters cGAS in the cytoplasm and sustains type I interferon responses to mitochondrial DNA.		0
46	Heterogeneity in viral replication dynamics shapes the antiviral response.		0
45	Pathophysiological Role of Nucleic Acid-Sensing Pattern Recognition Receptors in Inflammatory Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 12,	5.9	0
44	Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review. <i>Frontiers in Medicine</i> , 9,	4.9	1
43	Type-I Interferons in Alzheimer's Disease and Other Tauopathies. <i>Frontiers in Cellular Neuroscience</i> , 16,	6.1	1
42	IFN-I inducible miR-3614-5p targets ADAR1 isoforms and fine tunes innate immune activation. <i>Frontiers in Immunology</i> , 13,	8.4	
41	Exposing the Two Contrasting Faces of STAT2 in Inflammation.		
40	Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. <b>2022</b> , 14,		3

- 39 Characteristics and genetic analysis of patients suspected with early-onset systemic lupus erythematosus. **2022**, 20, ○
- 38 Generation of induced pluripotent stem cell lines from two patients with Aicardi-Goutières syndrome type 1 due to biallelic TREX1 mutations. **2022**, 64, 102895
- 37 Generation of induced pluripotent stem cell lines from three patients with Aicardi-Goutières syndrome type 5 due to biallelic SAMDH1 mutations. **2022**, 64, 102912 ○
- 36 Generation of a new Adar1p150<sup>-/-</sup> mouse demonstrates isoform-specific roles in embryonic development and adult homeostasis. ○
- 35 ER stress promotes mitochondrial DNA mediated type-1 interferon response in beta-cells and interleukin-8 driven neutrophil chemotaxis. 13, ○
- 34 DNA sensor associated type I Interferon signalling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids. 1
- 33 Alternative pathways driven by STING: From innate immunity to lipid metabolism. **2022**, 1
- 32 SPOP targets the immune transcription factor IRF1 for proteasomal degradation. ○
- 31 Unexpected little helpers: microbiota stimulate systemic antiviral defenses. **2022**, 7, ○
- 30 Common Variable Immunodeficiency: More Pathways than Roads to Rome. **2023**, 18, ○
- 29 Condensates, the place to hide self-immunostimulatory RNA. **2022**, 82, 3754-3755 ○
- 28 Deficiency for SAMHD1 activates MDA5 in a cGAS/STING-dependent manner. **2023**, 220, ○
- 27 Human IFNAR2 Mutant Generated by CRISPR/Cas9-Induced Exon Skipping Upregulates a Subset of Tonic-Like Interferon-Stimulated Genes Upon IFN $\beta$  Stimulation. **2022**, 42, 580-589 ○
- 26 The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement. 13, ○
- 25 Lysosomal Diseases. **2023**, 977-1028 ○
- 24 Glial interference: impact of type I interferon in neurodegenerative diseases. **2022**, 17, ○
- 23 An AGS-associated mutation in ADAR1 catalytic domain results in early-onset and MDA5-dependent encephalopathy with IFN pathway activation in the brain. **2022**, 19, ○
- 22 Precision medicine: The use of tailored therapy in primary immunodeficiencies. 13, ○

21	RNA modifications in cardiovascular health and disease.	1
20	Loss of the Immunomodulatory Transcription Factor BATF2 in Humans Is Associated with a Neurological Phenotype. <b>2023</b> , 12, 227	o
19	Glomerulonephritis: immunopathogenesis and immunotherapy.	1
18	Type-1 interferon-dependent and -independent mechanisms in cyclic GMPAMP synthase-stimulator of interferon genes-driven auto-inflammation. <b>2023</b> , 80, 102280	o
17	Genetic diagnosis of systemic autoinflammatory diseases and underlying primary immunodeficiency. <b>2022</b> , 19, 57-62	o
16	Diagnostic and therapeutic algorithms for monogenic autoinflammatory diseases presenting with recurrent fevers among adults.	o
15	Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy. <b>2023</b> , 100919	o
14	The inflammatory and tumor suppressor SAMD9L acts through a Schlafen-like box to restrict HIV and inhibit cell translation in SAAD/ATXPC.	o
13	Molecular Actors of Inflammation and Their Signaling Pathways: Mechanistic Insights from Zebrafish. <b>2023</b> , 12, 153	o
12	STING trafficking as a new dimension of immune signaling. <b>2023</b> , 220,	o
11	Pathogen-driven CRISPR screens identify TREX1 as a regulator of DNA self-sensing during influenza virus infection.	o
10	Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children. <b>2023</b> , 151, 607-618	o
9	Effector-Triggered Immunity. <b>2023</b> , 41,	o
8	GENEvRX: A Novel AI-Driven Method and Web Tool Can Identify Critical Genes and Effective Drugs for Lichen Planus.	o
7	Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. <b>2023</b> , 41,	o
6	SAMHD1 restricts the deoxyguanosine triphosphate pool contributing to telomere stability in telomerase-positive cells. <b>2023</b> , 37,	o
5	Human USP18 protects diverse cancer lineages from Type I Interferon independently of its canonical catalytic function.	o
4	SLC15A4 controls endolysosomal TLR7-9 responses by recruiting the innate immune adaptor TASL.	o

- 3 Interferonopathies de type I : d'un nouveau concept aux thérapeutiques ciblées. **2023**, ☐
- 2 Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia. **2023**, 41, 561-585 ☐
- 1 CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation. **2023**, 91, 104589 ☐